Patents Issued in April 30, 2020
-
Publication number: 20200129417Abstract: A cosmetic composition includes a non-acid-resistant-grade ultramarine dye, a stabilizing agent, at least one additive, and water. The ultramarine dye may be present at a concentration of about 0.1% to about 0.4%, by weight, of the cosmetic composition and may include a trisulfur radical anion. The stabilizing agent may include baicalin and may be at a concentration of about 0.2% or less, by weight, of the cosmetic composition. The cosmetic composition may have a pH in the range of 6.5 to 8.0. A method of stabilizing a cosmetic composition includes forming a cosmetic composition including a non-acid-resistant-grade ultramarine dye, a stabilizing agent, at least one additive, and water. The method also includes adjusting a pH of the cosmetic composition to a predetermined value. The stabilizing agent inhibits degradation of the ultramarine dye, thereby stabilizing the cosmetic composition and inhibiting generation of an odor caused by degradation of the ultramarine dye.Type: ApplicationFiled: October 24, 2018Publication date: April 30, 2020Inventors: Jonathan James FAIG, David CHAN
-
Publication number: 20200129418Abstract: A Chinese medical cosmetic composition comprising Radix Notoginseng extract, Aloe extract and Flos Lonicerae extract. The Chinese medical cosmetic composition has a scientific and reasonable formula composition, and has the effects of tonifying Qi and nourishing Yin, promoting blood circulation and removing blood stasis, moisturizing and whitening, and strengthening body and sun screening.Type: ApplicationFiled: October 30, 2018Publication date: April 30, 2020Inventor: Wen Liu
-
Publication number: 20200129419Abstract: A film forming composition comprises a film forming component and a solvent, wherein the film forming component comprises 0-50 wt % of a first water soluble polymer, 0.3-40 wt % of a second water soluble polymer, 0-15 wt % of plasticizer and 50-70 wt % of active ingredient. The first and second water soluble polymers have a Tg of ?52° C. to 216° C., and difference of Tg values of the first and second water soluble polymer is 62-268° C. The film formed by the film forming composition capable to load high content of active ingredient and lead to fast absorption of active ingredient is provided.Type: ApplicationFiled: March 13, 2018Publication date: April 30, 2020Applicant: Nano and Advanced Materials Institute LimitedInventors: Jinjie XU, Sau Kuen Connie KWOK, Wah Kit CHEUK, Ying LI, Pak Ho LAU
-
Publication number: 20200129420Abstract: An object of the invention is to provide a mucoadhesive oral preparation having high drug absorption rate and rapid drug release rate. The means for solving the problem is a mucoadhesive oral preparation having (a) a basal layer substantially consisting of a water-insoluble material, (b) a drug layer locating above the basal layer and containing a drug but not containing mucoadhesive material, and (c) an adhesive portion locating on a portion of the surface of the drug layer side of the oral formulation and containing mucoadhesive material.Type: ApplicationFiled: June 22, 2018Publication date: April 30, 2020Applicant: BIOSERENTACH CO., LTD.Inventor: Kanji TAKADA
-
Publication number: 20200129421Abstract: Provided herein is a system for delivery of a physiologically active agent to a user in need thereof, comprising: one or two appliances that correspond to an upper arch and/or lower dental arch of the user, each appliance comprising a labial/buccal side surface and a palatal/lingual side surface, a delivery module of a physiologically active agent, comprising the physiologically active agent, the one or two appliances comprise a body matrix of a polymeric material comprising polymeric shells, each shell having the geometry corresponding to one tooth of the dental arch(s) and configured to receive the one tooth, and the delivery module provides a controlled release of the physiologically active agent.Type: ApplicationFiled: October 24, 2019Publication date: April 30, 2020Inventor: Hui Feng
-
Publication number: 20200129422Abstract: A pharmaceutical mucoadhesive gel composition for delivering therapeutic agents (such as progesterone) by buccal, nasal, vaginal and rectal administration, thereby avoiding the hepatic first-pass metabolism. The gel composition comprises a vehicle with a gel-forming agent and a bioadhesive agent; and a therapeutic agent dispersed or suspended in the vehicle.Type: ApplicationFiled: October 25, 2019Publication date: April 30, 2020Inventors: William Bologna, François Boutignon, Lea Louvel, Finn Larsen, Simona Fiore, Oliver Bates
-
Publication number: 20200129423Abstract: The composition containing a pamoate salt of donepezil, the method of preparation and the use thereof are disclosed.Type: ApplicationFiled: October 31, 2019Publication date: April 30, 2020Inventor: Zi-Qiang Gu
-
Publication number: 20200129424Abstract: The present invention relates to a microneedle system (MNS) for intradermal application in a controlled release of glucagon-like peptide analogues.Type: ApplicationFiled: June 6, 2018Publication date: April 30, 2020Inventors: Andreas HENNING, Heiko SPILGIES
-
Publication number: 20200129425Abstract: Methods and compositions for systemically or locally administering by implantation a beneficial agent to a subject are described, and include, for example, depot gel compositions that can be injected into a desired location and which can provide controlled release of a beneficial agent over a short duration of time. The compositions include a low molecular weight biocompatible polymer, a biocompatible solvent having low water miscibility that forms a viscous gel with the polymer and limits water uptake by the implant, and a beneficial agent.Type: ApplicationFiled: September 26, 2019Publication date: April 30, 2020Inventors: Guohua Chen, David T. Priebe
-
Publication number: 20200129426Abstract: The purpose of the present invention is to provide a dosing technique for rifampicin, the technique being capable of long-term administration by enhancing the direct transfer of rifampicin to the brain and by suppressing the hepatic first-pass effect. This pharmaceutical composition for nasal administration, which contains, as an active ingredient, rifampicins selected from the group consisting of rifampicin, derivatives thereof, and salts thereof, and is used for the prevention or treatment of dementia, is capable of long-term administration by enhancing the direct transfer of rifampicin to the brain and suppressing the hepatic first-pass effect.Type: ApplicationFiled: July 5, 2018Publication date: April 30, 2020Inventors: Takami TOMIYAMA, Tomohiro UMEDA
-
Publication number: 20200129427Abstract: An improved method for manufacture of chewing gums containing active ingredient(s) that preserves the efficacy of the active ingredient(s) by avoiding exposure to high heat and extreme cold during milling that can otherwise degrade the active's efficacy. A chewing gum base is used, along with one or more therapcutically-active ingredients, one or more sweeteners (alcohol-based and/or natural), and one or more flavorings and optional flavor modifiers. The method generally comprises heating the gum base in ovens to melt the gum base. Separately, the active ingredient(s), sweeteners and flavorings are combined in a mixer. The melted gum base is added to the mixer and cools to produce a particulate mixture. As mixing continues the mass cools to room temperature and forms granular pieces. The granular pieces are ground into a powder at room temperature, mixed at room temperature with tableting excipients, and tableted. Several variations on the foregoing are also described.Type: ApplicationFiled: November 4, 2019Publication date: April 30, 2020Inventors: Lisa Bachmann, Robert Estey
-
Publication number: 20200129428Abstract: The invention relates to dry powder formulations comprising respirable dry particles that contain 1) an antifungal agent in crystalline particulate form, 2) a stabilizer, and 3) one or more excipients.Type: ApplicationFiled: October 13, 2017Publication date: April 30, 2020Inventors: Jason M. PERRY, Jean C. SUNG, David L. HAVA, Robert Clifford SAUNDERS, Hillary S. BERGSON, Andrew Emmet O'CONNOR
-
Publication number: 20200129429Abstract: Emulsions and layered compositions for improving thermal resistance of a substrate, such as a therapeutic or prophylactic medicinal substrate, are provided. Also provided are methods and kits for making the emulsions and layered compositions of the invention. The layered compositions and emulsions can be used to extend the shelf life of a product.Type: ApplicationFiled: March 15, 2018Publication date: April 30, 2020Applicant: Vivavax Inc.Inventors: Qi YANG, Winston DANG, Chad Gorman GROVES, Monir Riasad FADLE AZIZ, Ruby Rose RAFANAN
-
Publication number: 20200129430Abstract: A method for administering an active agent to a pleura of a patient includes preparing a composition including a foamable liquid and the active agent, incorporating a gas into the foamable liquid to create a foam containing the active agent, introducing the foam into a pleural cavity of the patient defined by the pleura, and contacting the pleura with the foam. A method of pleurodesis includes introducing a composition into a pleural cavity defined by pleurae of a patient, the composition including a foamable liquid and an active agent capable of causing inflammation and/or adhesion of the pleurae. A composition for treating a pleura of a patient includes a liquid component including a biocompatible composition having a viscosity which increases in response to an increase in temperature, and an active agent capable of causing inflammation and/or adhesion of the pleura.Type: ApplicationFiled: October 26, 2018Publication date: April 30, 2020Applicant: TDL Innovations LLCInventor: Glenn W. Laub
-
Publication number: 20200129431Abstract: A lipid membrane structure includes, as lipid components, a lipid compound represented by Formula (I): (R1)(R2)C(OH)—(CH3)a—(O—CO)b—X??(I) [in the formula, a represents an integer of 3 to 5; b represents an integer of 0 or 1; R1 and R2 each independently represents a linear hydrocarbon group that may have —CO—O—; and X represents a 5- to 7-membered non-aromatic heterocyclic group or a group represented by Formula (B) (in the formula, d represents an integer of 0 to 3, and R3 and R4 each independently represents a C1-4 alkyl group or a C2-4 alkenyl group, where, R3 and R4 may be bonded to each other to form a 5- to 7-membered non-aromatic heterocycle (where, one or two C1-4 alkyl groups or C2-4 alkenyl groups may be substituted on the ring)].Type: ApplicationFiled: June 15, 2018Publication date: April 30, 2020Inventors: Hideyoshi Harashima, Yusuke Sato
-
Publication number: 20200129432Abstract: Polynucleotides such as DNA are stored inside vesicles formed from self-assembling membranes. The vesicles may be protocells, liposome, micelles, colloidosomes, proteinosomes, or coacervates. The vesicles may include surface functionalization to improve polynucleotide encapsulation and/or to bind polynucleotides having specific sequences. Encapsulation in vesicles provides protection for the polynucleotides. Additional protection is provided by addition of one or more stabilizers. The stabilizer may be nucleic-acid stabilizers that stabilize the polynucleotides or may be a protective structural layer around the vesicles such as a layer of silica. A process for stably storing polynucleotides in vesicles and a process for recovering stored polynucleotides from vesicles are both disclosed. The polynucleotides may be used for storage of digital information.Type: ApplicationFiled: October 31, 2018Publication date: April 30, 2020Inventors: Karin STRAUSS, Bichlien Hoang NGUYEN
-
Publication number: 20200129433Abstract: The present invention relates to stem cell-derived microvesicles with enhanced efficacy, a use thereof, and a method for enhancing efficacy, and more particularly, to a use of stem cell-derived microvesicles with an enhanced expression level of microRNAs for the prevention or treatment of stroke, and a method for promoting the production of microRNAs of stem cell-derived microvesicles and enhancing efficacy, and a method for promoting the production of stem cell-derived microvesicles and microRNAs within the microvesicles and enhancing the efficacy of stem cells and microvesicles thereof by 3-dimensionally culturing or ischemically stimulating stem cells.Type: ApplicationFiled: October 14, 2019Publication date: April 30, 2020Inventors: Oh Young BANG, Eun Hee KIM, Jae Min CHA
-
Publication number: 20200129434Abstract: The present invention provides compositions comprising liposomes comprises cholesterol, phosphatidyl phosphoric acid and phosphatidyl choline, as well as liposomes comprising a drug or imaging agent and a peptide for targeting to the brain. The invention further provides methods for treating or ameliorating a brain disease by administering the compositions of the invention.Type: ApplicationFiled: April 18, 2018Publication date: April 30, 2020Inventors: Yeshayahu KATZ, Moshe GAVISH, Nahum ALLON, Martin GABAY, Meygal KAHANA
-
Publication number: 20200129435Abstract: Disclosed herein are embodiments of a composition comprising a matrix, a plurality of microparticles and a therapeutic agent. The therapeutic agent may be encapsulated in the microparticles, and/or the microparticles may be dispersed in the matrix. The composition may be a mesh or a sheet, and may further comprise a second therapeutic agent, and optionally a second microparticle and/or a second matrix. In particular embodiments, the matrix is a hydrogel. Methods for making and using the composition are also disclosed, and in certain embodiments, the composition is useful for treating cancer, such as brain cancer.Type: ApplicationFiled: October 24, 2018Publication date: April 30, 2020Applicants: UVic Industry Partnerships Inc., The University of British ColumbiaInventors: Mohsen Akbari, Brian Toyota
-
Publication number: 20200129436Abstract: Combining viral vector with surfactant preserves vector infectivity, and surfactant provided an unexpected benefit by protecting viral vector from damage due to transient elevated temperature.Type: ApplicationFiled: April 3, 2017Publication date: April 30, 2020Applicant: Trizell Ltd.Inventors: Minna HASSINEN, Robert SHAW, Nigel PARKER
-
Publication number: 20200129437Abstract: A finely divided binder in powder form consisting of a polyethylene glycol-polyvinyl alcohol graft polymer particles, wherein the particles have an average particle size D[4,3] in the range of from 10 to 70 ?m.Type: ApplicationFiled: June 5, 2018Publication date: April 30, 2020Inventors: Bernhard Fussnegger, Silke Gebert, Felicitas Guth, Karl Kolter
-
Publication number: 20200129438Abstract: The present application discloses a finished pharmaceutical dosage form comprising a low dose/high potency active pharmaceutical ingredient and one or more excipients. The active pharmaceutical ingredient in the present application has been blended and subsequently milled with at least one excipient before preparing the finished pharmaceutical dosage form. The disclosed finished dosage form promotes content uniformity and acceptable and reproducible dissolution rate and extent. Finished dosage forms of the present invention may comprise any active pharmaceutical ingredient; however, low solubility and/or high potency active pharmaceutical ingredients will particularly benefit. Among the low solubility and/or high potency active pharmaceutical ingredients, those with needle-like structures are even more particularly well suited for incorporation into the disclosed finished dosage forms.Type: ApplicationFiled: October 31, 2018Publication date: April 30, 2020Applicant: Edenbridge Pharmaceuticals, LLCInventor: David F. Erkoboni
-
Publication number: 20200129439Abstract: The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.Type: ApplicationFiled: December 31, 2019Publication date: April 30, 2020Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: Glenn A. MEYER, Cristian R. FRANCO, Gustavo A. FISCHBEIN, Claude E. WRIGHT
-
Publication number: 20200129440Abstract: The present invention relates to a complex preparation comprising clopidogrel, an HMG-CoA reductase inhibitor, and a separation membrane containing a hydrophobic compound. More particularly, an objective of the present invention is to provide the complex preparation comprising clopidogrel and the HMG-CoA reductase inhibitor, wherein the complex preparation is intended for preventing or treating a cardiovascular disease, which has excellent storage stability by preventing a decrease in the stability of the HMG-CoA reductase inhibitor.Type: ApplicationFiled: January 23, 2018Publication date: April 30, 2020Inventors: Nam Hyun Baek, Min Soo Choi, Ja Young Kim, Ji Young Woo, Seung Kyoo Seong, Young Jun Song, Ki Soo Seo, Woon Heo, Taeseong Jung
-
Publication number: 20200129441Abstract: Self-righting articles, such as self-righting capsules for administration to a subject, are generally provided. In some embodiments, the self-righting article may be configured such that the article may orient itself relative to a surface. The self-righting articles described herein may comprise one or more tissue engaging surfaces configured to engage with a surface. In some embodiments, the self-righting article may have a particular shape and/or distribution of density (or mass) which, for example, enables the self-righting behavior of the article. In some embodiments, the self-righting article may comprise a tissue interfacing component and/or a pharmaceutical agent (e.g., for delivery of the active pharmaceutical agent to a location internal of the subject). In some cases, upon contact of the tissue with the tissue engaging surface of the article, the self-righting article may be configured to release one or more tissue interfacing components.Type: ApplicationFiled: November 21, 2019Publication date: April 30, 2020Applicants: Massachusetts Intitute of Technology, Novo Nordisk A/S, The Brigham and Women's Hospital, Inc.Inventors: Alex G. Abramson, Morten Revsgaard Frederiksen, Brian Jensen, Mikkel Oliver Jespersen, Carlo Giovanni Traverso
-
Publication number: 20200129442Abstract: The present invention is related to polymer based formulation for release of drugs and bioactives at gastrointestinal tract specific sites including stomach, intestine and colon.Type: ApplicationFiled: April 10, 2018Publication date: April 30, 2020Inventors: Jayant Jagannath KHANDARE, Abhijit GOTHOSKAR, Nilesh KULKARNI, Gourishankar ALAND, Shashwat BANERJEE, Rituja GUPTA
-
Publication number: 20200129443Abstract: Embodiments of the present technology may include a method of forming an emulsion. The method may include flowing an oil stream and an aqueous stream into a coiled tube to form a mixture of an oil phase and an aqueous phase in the coiled tube. The method may also include flowing the mixture in the coiled tube against gravity and under laminar conditions. A plurality of beads may be disposed within the coiled tube. The method may further include mixing the oil phase and the aqueous phase in the coiled tube until the emulsion is formed.Type: ApplicationFiled: December 17, 2019Publication date: April 30, 2020Applicant: Rezolute, Inc.Inventors: Isaac J. Dillon, Kathleen M. Campbell, Sankaram Mantripragada
-
Publication number: 20200129444Abstract: Provided herein are devices and dosage forms useful in delivering macromolecular active ingredients or drugs, such as proteins, peptides and nucleic acids, through epithelial membranes, such as intestinal epithelium. Also provided are trans-epithelial drug delivery methods and methods of treatment of diabetes or insulin resistance, or to induce weight loss.Type: ApplicationFiled: July 13, 2018Publication date: April 30, 2020Inventors: Kathryn Ann Whitehead, Nicholas George Lamson
-
Publication number: 20200129445Abstract: The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include an ionizable lipid, a phospholipid, a first sterol or a tocopherol, and optionally a second sterol different from the first sterol. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.Type: ApplicationFiled: March 15, 2018Publication date: April 30, 2020Inventors: Siddharth PATEL, Emily ROBINSON, Anna BROWN, Orn ALMARSSON, Kerry E. BENENATO, Staci SABNIS, Gaurav SAHAY, Ashwani Kumar NARAYANA
-
Publication number: 20200129446Abstract: Disclosed are compositions and methods for vaccinating susceptible individuals against infection by respiratory syncytial virus (RSV). The disclosed compositions include vaccine compositions comprising an effective amount of respiratory syncytial virus (RSV) F protein in a pre-fusion stabilized form and/or M protein incorporated into biodegradable polyanhydride polymer particles for inducing an immune response against RSV. The vaccine compositions also may include a suitable adjuvant.Type: ApplicationFiled: October 28, 2019Publication date: April 30, 2020Applicant: University of Iowa Research FoundationInventors: Steven M. Varga, Kevin L. Legge
-
Publication number: 20200129447Abstract: Provided are polymers (e.g., polymeric materials), nanoparticles comprising one or more of the polymers, and compositions. A polymer may be in the form of a nanoparticle. A polymer can be linear or branched. A polymer includes one or more poly(ester urea) segment, optionally, one or more poly(urethane) segment, optionally, one or more diol segment, optionally, one or more poly(ethylene glycol) segment, and, optionally, one or more terminal/end group. A polymer (e.g., a polymeric material) may include a branching moiety. For example, a composition includes one or more polymer. In an example, polymers and nanoparticles can be used to deliver a drug (e.g., gambogic acid) to an individual (e.g, who has been diagnosed with or is suspected of having cancer and/or a viral infection).Type: ApplicationFiled: September 20, 2017Publication date: April 30, 2020Inventors: Chih-Chang CHU, Mingyu HE, Ying JI
-
Publication number: 20200129448Abstract: The current disclosure provides compositions and methods for wound closure. The disclosure provides an device comprising: a) a material with a surface comprising a modified fibrinogen or a modified fibrin, wherein the modified fibrinogen or modified fibrin is more resistant to fibrinolysis than an unmodified fibrinogen or an unmodified fibrin, respectively; and b) one or more dispersible fibrinolysis inhibitors in contact with the surface comprising a plasmin inhibitor; and c) optionally, a thrombin agent or platelets.Type: ApplicationFiled: July 13, 2018Publication date: April 30, 2020Inventors: Christopher D. BARRETT, Michael B. YAFFE, Ernest E. MOORE, Hunter B. MOORE, Michael P. CHAPMAN
-
Publication number: 20200129449Abstract: Compounds, compositions, and methods of use of such compounds and compositions are provided for reducing human dependency to nicotine. In one example, a method of treating an individual with an addiction to nicotine comprises administering to the individual a compound that is a structural analog of trans-cinnamaldehyde. Based on the administration, a rate at which nicotine is metabolized may be reduced, which in turn may reduce a desire for the individual to consume nicotine-containing products.Type: ApplicationFiled: October 24, 2019Publication date: April 30, 2020Inventors: John P. Harrelson, Deepa A. Rao
-
Publication number: 20200129450Abstract: The present invention relates to a composition comprising osmundacetone or a pharmaceutically acceptable salt thereof for preventing or treating bone diseases. More specifically, the present invention relates to: a composition comprising osmundacetone, a pharmaceutically acceptable salt thereof, or an Osmunda japonica extract as an effective ingredient, for preventing or treating osteoporosis, rheumatoid arthritis, arthralgia, Paget disease, bone metastatic cancer, or fracture; a food composition for improvement; a use of a salt; and a treatment method.Type: ApplicationFiled: September 28, 2017Publication date: April 30, 2020Inventors: Gil Hong Park, Geu Rim Son, Seong Su Hong, Chun Whan Choi, Yun Hyeok Choi, Woo Jung Kim, Han Kyeom Kim, Jae Woo Kang, Eun Jung Lee, Serk In Park, Kee Ho Lee, Min Ji Choi
-
Publication number: 20200129451Abstract: The present invention refers to the use of the compound Cur-[G-2]-OH as a sensitizing agent in a wide range of multidrug-resistant tumors, especially glioblastoma, which are characterized by overexpression of the Nrf2 pathway.Type: ApplicationFiled: July 6, 2018Publication date: April 30, 2020Applicant: Instituto Nacional de Neurologia Y NeurocirugiaInventor: Irma Gabriela Gonzalez Herrera
-
Publication number: 20200129452Abstract: In order to make available the health-promoting and healing properties of curcumin to the human or animal organism, also in combination with at least one further active substance, a solubilizate consists of or contains a content of curcumin equal to or smaller than 10 wt %, preferably equal to or smaller than 7.5 wt %, most preferably 6 wt %, and at least one emulsifier with an HLB value in a range below 18, preferably between 13 and 18, namely polysorbate 80 or polysorbate 20 or a mixture of polysorbate 20 and polysorbate 80, with an average diameter of the curcumin-loaded micelles ranging from 5 nm to 40 nm, preferably from 6 nm to 20 nm, most preferably from 7 nm to 10 nm, for use in particular as a dietary supplement and/or pharmaceutical drug for treating and/or preventing diseases involving inflammation, cancer and other diseases.Type: ApplicationFiled: July 11, 2018Publication date: April 30, 2020Applicant: Aquanova AGInventor: Dariush BEHNAM
-
Publication number: 20200129453Abstract: A method of treating an ocular disorder in a subject associated with increased all-trans-retinal in an ocular tissue includes administering to the subject a therapeutically effective amount of a primary amine compound of formula (I): and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: July 30, 2019Publication date: April 30, 2020Inventor: Krzysztof Palczewski
-
Publication number: 20200129454Abstract: The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: October 31, 2019Publication date: April 30, 2020Inventors: Glenn A. MEYER, Joaquina FAOUR, Ana Cristina PASTINI, Marcelo Fernando BEFUMO
-
Publication number: 20200129455Abstract: The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: October 31, 2019Publication date: April 30, 2020Inventors: Glenn A. MEYER, Joaquina FAOUR, Ana Cristina PASTINI, Marcelo Fernando BEFUMO
-
Publication number: 20200129456Abstract: A pharmaceutically acceptable composition and method of therapy for a kinase-dependent malignancy in a patient in need of such therapy is provided. The composition contains, as the only active agents, the combination of (a) an inhibitor of c-Fos, (b) an inhibitor of Dusp-1, and (c) an inhibitor of a tyrosine kinase. The composition is administered to the patient in a dosing regimen for a period sufficient to provide therapy for kinase-dependent malignancy. Also provided is a method to eradicate leukemia initiating cells (LIC) or cancer stem cells (CSC) in a patient being treated with a tyrosine kinase inhibitor.Type: ApplicationFiled: June 28, 2019Publication date: April 30, 2020Inventors: Mohammad AZAM, Meenu KESARWANI
-
Publication number: 20200129457Abstract: The present disclosure relates to small molecule or polymer conjugated MetAP2 inhibitors. The present disclosure also relates to methods of treating, or ameliorating at least one symptom of metabolic dysfunction associated with a treatment in a subject having a disease, such as cancer. The present disclosure also relates to methods of treating, or ameliorating at least one symptom of cancer comprising administering a combination of a polymer conjugated MetAP2 inhibitors and at least one second agent wherein the second agent may induce metabolic dysfunction.Type: ApplicationFiled: October 28, 2019Publication date: April 30, 2020Inventors: Peter CORNELIUS, James SHANAHAN
-
Publication number: 20200129458Abstract: Compounds represented by formula (I): wherein each symbol is as defined in the present specification, or a salt thereof are useful for the prophylaxis or treatment of diabetes and obesity, and diseases related thereto.Type: ApplicationFiled: December 27, 2019Publication date: April 30, 2020Applicant: AJINOMOTO CO., INC.Inventors: Tomohiro FUJII, Koji Ohsumi, Seiji Kitajima, Yoshiro Kitahara
-
Publication number: 20200129459Abstract: A new use of 2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl] acetic acid (sulindac) of the formula 1 for making the pharmaceutical preparations for the treatment of difficult healing different types of wounds in patients with diabetes. The medical use of 2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl] acetic acid (sulindac) of the formula 1 shown in the FIG. 1 for the preparation of pharmaceutical formulations for the treatment of difficult healing different types of wounds in patients with diabetes is disclosed.Type: ApplicationFiled: April 11, 2018Publication date: April 30, 2020Inventor: MIKOLAJ TOMULEWICZ
-
Publication number: 20200129460Abstract: Treatment of intrahepatic cholestatic diseases by therapy with seladelpar or a salt thereof.Type: ApplicationFiled: November 6, 2019Publication date: April 30, 2020Inventors: Pol Boudes, Charles A. McWherter
-
Publication number: 20200129461Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.Type: ApplicationFiled: December 28, 2019Publication date: April 30, 2020Applicant: Infirst Healthcare LimitedInventors: Robin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley
-
Publication number: 20200129462Abstract: Disclosed are compositions, methods of treatment using the compositions and methods of preparing the compositions for the treatment of acne vulgaris. The compositions include succinic acid, Brij®-30 and a molecular penetration enhancer in a pharmaceutically acceptable preparation. The molecular penetration enhancer may include one or more of DMSO, dimethyl isosorbide, lauryl lactate and isopropyl myristate.Type: ApplicationFiled: May 25, 2017Publication date: April 30, 2020Applicant: Dermala Inc.Inventors: Lada RASOCHOVA, Edward T KISAK, John NEWSAM
-
Publication number: 20200129463Abstract: In various implementations, cannabidiol, beta-hydroxybutyrate, related compounds, and/or one or more other compounds may be administered to an individual to improve the health of the individual. Other compounds may include amino acids, short chain fatty acids, short chain triglycerides, medium chain fatty acids, medium chain triglycerides, long chain fatty acids, long chain triglycerides, berberine, metabolites of berberine (e.g., dihydroberberine), and/or combinations thereof.Type: ApplicationFiled: October 29, 2019Publication date: April 30, 2020Inventors: Ryan Lowery, Jacob Wilson, Terry LaCore
-
Publication number: 20200129464Abstract: A method and composition for improving the health of a mammal, such as by increasing the bioavailability of L-carnitine to the mammal. The method and composition includes administering an effective amount of branched chain amino acid metabolite substituted carnitine compound. The method and composition also includes administering an effective amount of branched chain amino acid metabolite substituted carnitine compound in order to improve the health of the mammal. The mammal's health may be improved by providing increased energy, anti-aging, anti-inflammatory and/or anti-oxidant properties, increased mitochondrial function, increased brain function, weight management and/or obesity management properties, exercise endurance and exercise recovery, increased protein synthesis, mTOR pathway activation, and/or Kreps cycle stimulation.Type: ApplicationFiled: October 28, 2019Publication date: April 30, 2020Inventor: Aouatef Bellamine
-
Publication number: 20200129465Abstract: Amino acid formulations for pancreatic vitality. The formulations comprise a mixture of a plurality of amino acids, wherein the mixture comprises at least one amino acid selected from the group consisting of serine, glutamic acid, and/or carnitine. Methods of enhancing pancreatic vitality, stabilizing blood glucose levels, and improving A1C levels in subjects in need thereof are also described.Type: ApplicationFiled: April 24, 2018Publication date: April 30, 2020Inventors: Stacy Tucker, Sushrutha Nagaraj
-
Publication number: 20200129466Abstract: Provided herein are compositions and methods useful for the treatment of anhidrosis in mammals, for example, horses.Type: ApplicationFiled: December 31, 2019Publication date: April 30, 2020Inventors: Mark Herthel, Meri Stratton-Phelps